GRC-6211 is a drug developed by
Glenmark Pharmaceuticals which acts as a potent and selective
antagonist for the
TRPV1 receptor. It has
analgesic and
antiinflammatory effects and reached
Phase IIb human trials, but was ultimately discontinued from development as a medicine, though it continues to have applications in scientific research.[1][2][3]
References
^Charrua A, Cruz CD, Narayanan S, Gharat L, Gullapalli S, Cruz F, Avelino A (January 2009). "GRC-6211, a new oral specific TRPV1 antagonist, decreases bladder overactivity and noxious bladder input in cystitis animal models". The Journal of Urology. 181 (1): 379–86.
doi:
10.1016/j.juro.2008.08.121.
PMID19010489.
^Santos-Silva A, Charrua A, Cruz CD, Gharat L, Avelino A, Cruz F (January 2012). "Rat detrusor overactivity induced by chronic spinalization can be abolished by a transient receptor potential vanilloid 1 (TRPV1) antagonist". Autonomic Neuroscience. 166 (1–2): 35–8.
doi:
10.1016/j.autneu.2011.09.005.
PMID22037502.
S2CID7146812.
GRC-6211 is a drug developed by
Glenmark Pharmaceuticals which acts as a potent and selective
antagonist for the
TRPV1 receptor. It has
analgesic and
antiinflammatory effects and reached
Phase IIb human trials, but was ultimately discontinued from development as a medicine, though it continues to have applications in scientific research.[1][2][3]
References
^Charrua A, Cruz CD, Narayanan S, Gharat L, Gullapalli S, Cruz F, Avelino A (January 2009). "GRC-6211, a new oral specific TRPV1 antagonist, decreases bladder overactivity and noxious bladder input in cystitis animal models". The Journal of Urology. 181 (1): 379–86.
doi:
10.1016/j.juro.2008.08.121.
PMID19010489.
^Santos-Silva A, Charrua A, Cruz CD, Gharat L, Avelino A, Cruz F (January 2012). "Rat detrusor overactivity induced by chronic spinalization can be abolished by a transient receptor potential vanilloid 1 (TRPV1) antagonist". Autonomic Neuroscience. 166 (1–2): 35–8.
doi:
10.1016/j.autneu.2011.09.005.
PMID22037502.
S2CID7146812.